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Willemijn Meijer was born in Meppel on February 4, 1976. In 1994 she started studying 
Pharmacy in Groningen where she received her Master’s in pharmacoepidemiology in 1999. 
Her master thesis about the association between ovulation inducing drugs and birth defects 
was written in Århus, Denmark. In 2001 she received her Pharmaceutical degree. During her 
studies, Willemijn was appointed as teaching assistant several times to teach fourth grade 
students research methodology. She also had several assistantships at the Science Shop. 
Furthermore, she worked in a pharmacy in Groningen for a few months. 
 In September 2001, Willemijn started as a researcher at Social Pharmacy, 
Pharmacoepidemiology and Pharmacotherapy in Groningen on a project about introducing a 
folic acid intervention in daily practice of pharmacies. In January 2002 she was appointed a 
PhD student at the same group to study drug use before and during pregnancy and the risk 
on birth defects. In 2004, she also worked at the Eurocat Northern Netherlands registry of 
congenital anomalies for seven months. As a part of the PhD project, Willemijn visited the 
Slone Epidemiology Center of the Boston University, US, between November 2005 and 
February 2006 to study whether folic acid protects against heart defects among children with 
Down syndrome. This all resulted in her thesis titled “Drug safety in pregnancy. Studying 
and communicating teratogenic risks” which she will defend on December 8, 2006. Since 
August 2006, Willemijn has been working as a research associate at the Pharmo Institute for 
drug outcomes research in Utrecht.  
 Willemijn is a member of the Royal Dutch Pharmaceutical Society (KNMP), the  
Netherlands Epidemiological Society (VvE) and the International Society for 
Pharmacoepidemiology (ISPE).  
 
  
 
